An allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...

Spinal cord injury (SCI) remains the most serious complication of repairing descending thoracic and thoracoabdominal aortic aneurysms, with endovascular ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

Nerve cells in the spinal cord do not regenerate easily and scar tissue forms quickly ... and improving recovery. Shortly after the injury, steroid medications and surgery are used to help reduce ...

A neurosurgeon and a neuroscientist discover promising new ways to help people with spinal cord injuries walk again ...

Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...

A new FDA-approved device is bringing hope to people who have suffered spinal injuries and helping them regain function they ...

UW Medicine is unveiling an FDA-approved spinal cord therapy in an effort to offer new hope for paralyzed patients.

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...